home / stock / snti / snti news

SNTI News and Press, Senti Biosciences Inc.

Stock Information
Company Name: Senti Biosciences Inc.
Stock Symbol: SNTI
Market: NASDAQ
Website: sentibio.com
Menu
Get SNTI Alerts

News, Short Squeeze, Breakout and More Instantly...
SNTI - Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that  Ti...
SNTI - Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy...

SNTI - Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will pr...

SNTI - Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Access the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its pr...
SNTI - Expected earnings - Senti Biosciences Inc.

Senti Biosciences Inc. (SNTI) is expected to report for Q2 2025

SNTI - Senti Biosciences GAAP EPS of -$0.56

2025-08-07 09:39:42 ET More on Senti Biosciences Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Senti Biosciences Financial information for Senti Biosciences Read the full article on Seeking Alpha For further det...

SNTI - Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial result...
SNTI - Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it has confirme...

SNTI - Senti Biosciences Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy ...

SNTI - JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live

- Video webcasts from participating companies now available here FRENCHTOWN, NJ / ACCESS Newswire / July 22, 2025 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the Virtual Investor "What's Your Story" Summer Spotli...
Next 10